Developer docs
API playgroundTry for free, no card

Search company profiles

Epion Therapeutics

Full company profile

uuid0002b8r

Namestring
Epion Therapeutics
Legal namestring
Epion Therapeutics, Inc.
Websiteurl
epiontx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Epion Therapeutics, Inc. is a clinical-stage ophthalmic biopharmaceutical company developing EpiSmart, a drug-device combination system for minimally invasive epithelium-on (epi-on) corneal cross-linking to treat keratoconus and other ectatic corneal diseases. The company originated as CXL Ophthalmics, LLC in 2017, rebranded to Epion Therapeutics in July 2023, and is headquartered in Burlington, Massachusetts with 1–10 employees. The EpiSmart system integrates three proprietary components: EpiPrep (a disposable wand and loading sponge for epithelial drug delivery), RiboStat (a fixed-dose combination of riboflavin 0.5% and sodium iodide 0.015% that eliminates the need for supplemental oxygen and removes cytotoxic hydrogen peroxide byproducts), and a dual-head UV-A light device that enables simultaneous bilateral treatment via a proprietary light cycling protocol. The product is protected by at least 12 US and 3 European patents covering the device, drug formulation, and applicator methods.

The company completed Phase 3 Apricity clinical trials in June 2026, the largest epi-on cross-linking program to date with approximately 800 patients across 26 US sites, and was granted FDA Fast Track designation in October 2025. Backed by $50.5M in disclosed funding — including a $32M Series A led by AXA IM Alts in September 2022 and an $18.5M financing round led by OCULUS Optikgeräte GmbH in October 2025 — Epion is positioned for NDA submission and subsequent US commercialization through traditional ophthalmic channels.

Epion's go-to-market is pre-commercial: the company currently runs 26 Phase 3 investigational sites and plans to commercialize post-FDA-approval via direct sales to ophthalmologists, corneal specialists, and specialty eye clinics treating keratoconus patients aged 8 and older. The OCULUS partnership provides commercial-scale engineering, manufacturing, and a global ophthalmic distribution platform (Pentacam-installed base across Europe, Asia, and the Americas) for device production and potential international expansion. Pricing has not been disclosed, and the company does not yet generate revenue.

Short descriptiontext

Epion Therapeutics is a clinical-stage ophthalmic biopharmaceutical company developing EpiSmart, a drug-device combination for minimally invasive epithelium-on corneal cross-linking to treat keratoconus, currently completing Phase 3 trials ahead of an NDA submission.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBurlington, United States
HQ citystring
Burlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
corneal cross-linking, keratoconus treatment, ophthalmic medical devices, drug-device combination, epithelium-on cross-linking
Industry2 codes
PRIMARYHLAHAJAK
Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Ophthalmic medical devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1EpiSmart Cross-Linking System
TypeHardware Sales
Description

As a late-stage clinical company, Epion does not yet generate revenue. Upon FDA approval, the company expects to commercialize its EpiSmart epithelium-on cross-linking system as a medical device pharmaceutical combination product sold to ophthalmologists and corneal specialists for keratoconus treatment.

epiontx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1EpiSmart™
Description

EpiSmart™ Epithelium-On Cross-Linking System is a drug-device combination designed to treat keratoconus, combining proprietary drug delivery devices, fixed-dose combination drug (RiboStat), and a patented UVA light device for simultaneous bilateral treatment.

epiontx.com
+2 more records
Core offering1 text field

Epion Therapeutics is developing EpiSmart, a drug-device combination system for treating keratoconus (a progressive corneal ectatic disease) using transepithelial (epithelium-on) corneal cross-linking. The system integrates three proprietary components: the EpiPrep drug delivery wand and sponge, the RiboStat riboflavin-sodium iodide formulation, and a dual-head UVA light device that enables simultaneous bilateral treatment without surgical removal of the corneal epithelium.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 80% of patients maintained or improved corrected distance visual acuity at 12 months post-treatment
+5 more records
Product overview1 text field

Epion Therapeutics is a clinical-stage ophthalmic company developing EpiSmart, a transformative cross-linking system for treating keratoconus. The system is a drug-device combination consisting of three integrated components: EpiPrep (disposable wand and loading sponge for epithelial drug delivery), RiboStat (fixed-dose riboflavin and sodium iodide formulation), and a dual-head UVA light device. Unlike traditional epi-off cross-linking that requires surgical removal of the corneal epithelium, EpiSmart preserves the epithelium, enabling simultaneous bilateral treatment, reduced discomfort, and faster recovery. The system is currently in Phase 3 clinical trials and has received FDA Fast Track designation.

Product and service1 record
1EpiSmart Epithelium-On Cross-Linking System
CategoryOphthalmic medical devices
Description

A drug-device combination designed to treat keratoconus, a progressive corneal disease. The system combines proprietary drug delivery devices (EpiPrep), a fixed-dose combination drug (RiboStat), and a patented dual-head UVA light device to perform epithelium-on (epi-on) corneal cross-linking without disrupting the corneal epithelium. It enables simultaneous bilateral treatment, treatment at diagnosis without documented progression, and rapid return to normal activities (1-2 days).

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-07
Description

OCULUS partnered through an $18.5M financing round and strategic partnership. OCULUS is a world leader in ophthalmic and optometric devices including the Pentacam, the gold standard for keratoconus detection. OCULUS will apply its engineering expertise to development and manufacturing of the EpiSmart UVA therapeutic device. OCULUS operates 12 subsidiaries across Europe, Asia, and the Americas with over 125 years of experience.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Emerging clinical-stage company developing proprietary drug delivery approaches for corneal cross-linking and other ophthalmic indications. Direct emerging competitor in the epi-on cross-linking space pursuing similar minimally-invasive therapeutic positioning.

2Carl Zeiss Meditec
TypeBroad incumbent
Description

Major ophthalmic device manufacturer offering diagnostic and surgical ophthalmology equipment. Competitively adjacent through ophthalmic surgical workflows, refractive surgery, and corneal diagnostics that intersect with keratoconus management.

TypeBroad incumbent
Description

Largest pure-play ophthalmic device and pharmaceutical company globally, with surgical, vision care, and pharmaceutical franchises. Competes across ophthalmic surgery, dry eye, and refractive markets that overlap with keratoconus treatment pathways.

TypeDirect peer
Description

Acquired Avedro in 2019 and now commercializes Photrexa Vibe, the only FDA-approved epi-off corneal cross-linking treatment for keratoconus in the US. Directly competes with EpiSmart in the keratoconus cross-linking market but with an epi-off rather than epi-on approach.

TypeBroad incumbent
Description

Japanese ophthalmic and optometric equipment manufacturer offering diagnostic, surgical, and refractive devices. Relevant peer in corneal diagnostics, refractive surgery, and ophthalmic device manufacturing categories overlapping with EpiSmart.

TypeBroad incumbent
Description

Major ophthalmic device and vision care franchise (including former Abbott Medical Optics). Competes broadly in corneal, refractive, and cataract surgery devices; multiple Epion board members and executives previously held senior roles at J&J Vision.

TypeOthers
Description

Strategic partner and investor in Epion; manufacturer of the Pentacam, the gold standard for keratoconus detection/diagnosis. Highly relevant comparison point as the diagnostic upstream gatekeeper for the keratoconus patient funnel that EpiSmart addresses.

TypeBroad incumbent
Description

Ophthalmic diagnostic and imaging equipment manufacturer, including corneal topography and tomography systems used for keratoconus diagnosis. Adjacent competitive positioning in keratoconus diagnostic and management workflows.

TypeBroad incumbent
Description

Global ophthalmic medical device and pharmaceutical company with historical involvement in corneal cross-linking (acquired certain CXL assets). Broad ophthalmic portfolio competes for keratoconus patient management and surgical ophthalmology market share.

TypeDirect peer
Description

Originally an independent company that developed and commercialized FDA-approved cross-linking technology (Photrexa/Phorcera) for keratoconus and post-LASIK ectasia. Acquired by Glaukos in 2019; remains the directly competitive epi-off cross-linking standard against which EpiSmart will compete.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Epion Therapeutics

Ophthalmic medical devicesepiontx.com

Epion Therapeutics is a clinical-stage ophthalmic biopharmaceutical company developing EpiSmart, a drug-device combination for minimally invasive epithelium-on corneal cross-linking to treat keratoconus, currently completing Phase 3 trials ahead of an NDA submission.

What Epion Therapeutics does

Epion Therapeutics, Inc. is a clinical-stage ophthalmic biopharmaceutical company developing EpiSmart, a drug-device combination system for minimally invasive epithelium-on (epi-on) corneal cross-linking to treat keratoconus and other ectatic corneal diseases. The company originated as CXL Ophthalmics, LLC in 2017, rebranded to Epion Therapeutics in July 2023, and is headquartered in Burlington, Massachusetts with 1–10 employees. The EpiSmart system integrates three proprietary components: EpiPrep (a disposable wand and loading sponge for epithelial drug delivery), RiboStat (a fixed-dose combination of riboflavin 0.5% and sodium iodide 0.015% that eliminates the need for supplemental oxygen and removes cytotoxic hydrogen peroxide byproducts), and a dual-head UV-A light device that enables simultaneous bilateral treatment via a proprietary light cycling protocol. The product is protected by at least 12 US and 3 European patents covering the device, drug formulation, and applicator methods.

The company completed Phase 3 Apricity clinical trials in June 2026, the largest epi-on cross-linking program to date with approximately 800 patients across 26 US sites, and was granted FDA Fast Track designation in October 2025. Backed by $50.5M in disclosed funding — including a $32M Series A led by AXA IM Alts in September 2022 and an $18.5M financing round led by OCULUS Optikgeräte GmbH in October 2025 — Epion is positioned for NDA submission and subsequent US commercialization through traditional ophthalmic channels.

Epion's go-to-market is pre-commercial: the company currently runs 26 Phase 3 investigational sites and plans to commercialize post-FDA-approval via direct sales to ophthalmologists, corneal specialists, and specialty eye clinics treating keratoconus patients aged 8 and older. The OCULUS partnership provides commercial-scale engineering, manufacturing, and a global ophthalmic distribution platform (Pentacam-installed base across Europe, Asia, and the Americas) for device production and potential international expansion. Pricing has not been disclosed, and the company does not yet generate revenue.

Epion Therapeutics firmographics

Firmographics
Name
Epion Therapeutics
Legal name
Epion Therapeutics, Inc.
Website
https://epiontx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Epion Therapeutics is a clinical-stage ophthalmic biopharmaceutical company developing EpiSmart, a drug-device combination for minimally invasive epithelium-on corneal cross-linking to treat keratoconus, currently completing Phase 3 trials ahead of an NDA submission.
Ownership category
akta.pro rank

Epion Therapeutics industry classification

Industry
Product category
Ophthalmic medical devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAJAK
Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Corneal cross-linking
  • Keratoconus treatment
  • Ophthalmic medical devices
  • Drug-device combination
  • Epithelium-on cross-linking

Where Epion Therapeutics is headquartered

Location

Headquarters

HQ city
Burlington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Epion Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. EpiSmart Cross-Linking System: As a late-stage clinical company, Epion does not yet generate revenue. Upon FDA approval, the company expects to commercialize its EpiSmart epithelium-on cross-linking system as a medical device pharmaceutical combination product sold to ophthalmologists and corneal specialists for keratoconus treatment.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Epion Therapeutics product offering

Product offering

Core offering

Epion Therapeutics is developing EpiSmart, a drug-device combination system for treating keratoconus (a progressive corneal ectatic disease) using transepithelial (epithelium-on) corneal cross-linking. The system integrates three proprietary components: the EpiPrep drug delivery wand and sponge, the RiboStat riboflavin-sodium iodide formulation, and a dual-head UVA light device that enables simultaneous bilateral treatment without surgical removal of the corneal epithelium.

Product overview

Epion Therapeutics is a clinical-stage ophthalmic company developing EpiSmart, a transformative cross-linking system for treating keratoconus. The system is a drug-device combination consisting of three integrated components: EpiPrep (disposable wand and loading sponge for epithelial drug delivery), RiboStat (fixed-dose riboflavin and sodium iodide formulation), and a dual-head UVA light device. Unlike traditional epi-off cross-linking that requires surgical removal of the corneal epithelium, EpiSmart preserves the epithelium, enabling simultaneous bilateral treatment, reduced discomfort, and faster recovery. The system is currently in Phase 3 clinical trials and has received FDA Fast Track designation.

Differentiator

Problem solved

Functional benefit

Brands

  • EpiSmart™: EpiSmart™ Epithelium-On Cross-Linking System is a drug-device combination designed to treat keratoconus, combining proprietary drug delivery devices, fixed-dose combination drug (RiboStat), and a patented UVA light device for simultaneous bilateral treatment.
  • RiboStat™
  • EpiPrep™

Products and services

  • EpiSmart Epithelium-On Cross-Linking System A drug-device combination designed to treat keratoconus, a progressive corneal disease. The system combines proprietary drug delivery devices (EpiPrep), a fixed-dose combination drug (RiboStat), and a patented dual-head UVA light device to perform epithelium-on (epi-on) corneal cross-linking without disrupting the corneal epithelium. It enables simultaneous bilateral treatment, treatment at diagnosis without documented progression, and rapid return to normal activities (1-2 days).

Quantifiable outcome

  • 80% of patients maintained or improved corrected distance visual acuity at 12 months post-treatment
  • +5 more outcomes

Companies that use Epion Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Epion Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Epion Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • OCULUS Optikgeräte GmbHcoreStrategic or Co-development Partner · 7 October 2025OCULUS partnered through an $18.5M financing round and strategic partnership. OCULUS is a world leader in ophthalmic and optometric devices including the Pentacam, the gold standard for keratoconus detection. OCULUS will apply its engineering expertise to development and manufacturing of the EpiSmart UVA therapeutic device. OCULUS operates 12 subsidiaries across Europe, Asia, and the Americas with over 125 years of experience.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Epion Therapeutics competitors and assessment

Company assessment

Emerging players

  • iVeena Delivery Systems: Emerging clinical-stage company developing proprietary drug delivery approaches for corneal cross-linking and other ophthalmic indications. Direct emerging competitor in the epi-on cross-linking space pursuing similar minimally-invasive therapeutic positioning.

Broad incumbents

  • Carl Zeiss Meditec: Major ophthalmic device manufacturer offering diagnostic and surgical ophthalmology equipment. Competitively adjacent through ophthalmic surgical workflows, refractive surgery, and corneal diagnostics that intersect with keratoconus management.
  • Alcon: Largest pure-play ophthalmic device and pharmaceutical company globally, with surgical, vision care, and pharmaceutical franchises. Competes across ophthalmic surgery, dry eye, and refractive markets that overlap with keratoconus treatment pathways.
  • Nidek Co., Ltd. Japanese ophthalmic and optometric equipment manufacturer offering diagnostic, surgical, and refractive devices. Relevant peer in corneal diagnostics, refractive surgery, and ophthalmic device manufacturing categories overlapping with EpiSmart.
  • Johnson & Johnson Vision: Major ophthalmic device and vision care franchise (including former Abbott Medical Optics). Competes broadly in corneal, refractive, and cataract surgery devices; multiple Epion board members and executives previously held senior roles at J&J Vision.
  • Topcon Healthcare: Ophthalmic diagnostic and imaging equipment manufacturer, including corneal topography and tomography systems used for keratoconus diagnosis. Adjacent competitive positioning in keratoconus diagnostic and management workflows.
  • Bausch + Lomb (Bausch Health): Global ophthalmic medical device and pharmaceutical company with historical involvement in corneal cross-linking (acquired certain CXL assets). Broad ophthalmic portfolio competes for keratoconus patient management and surgical ophthalmology market share.

Direct peers

  • Glaukos Corporation: Acquired Avedro in 2019 and now commercializes Photrexa Vibe, the only FDA-approved epi-off corneal cross-linking treatment for keratoconus in the US. Directly competes with EpiSmart in the keratoconus cross-linking market but with an epi-off rather than epi-on approach.
  • Avedro (now part of Glaukos): Originally an independent company that developed and commercialized FDA-approved cross-linking technology (Photrexa/Phorcera) for keratoconus and post-LASIK ectasia. Acquired by Glaukos in 2019; remains the directly competitive epi-off cross-linking standard against which EpiSmart will compete.

Others

  • OCULUS Optikgeräte GmbH: Strategic partner and investor in Epion; manufacturer of the Pentacam, the gold standard for keratoconus detection/diagnosis. Highly relevant comparison point as the diagnostic upstream gatekeeper for the keratoconus patient funnel that EpiSmart addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Epion Therapeutics social profiles

Digital presence

Epion Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Epion Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Epion Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Epion Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epion Therapeutics

What does Epion Therapeutics do?

Epion Therapeutics is developing EpiSmart, a drug-device combination system for treating keratoconus (a progressive corneal ectatic disease) using transepithelial (epithelium-on) corneal cross-linking. The system integrates three proprietary components: the EpiPrep drug delivery wand and sponge, the RiboStat riboflavin-sodium iodide formulation, and a dual-head UVA light device that enables simultaneous bilateral treatment without surgical removal of the corneal epithelium.

Is Epion Therapeutics a public or private company?

Epion Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Epion Therapeutics founded?

Epion Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is Epion Therapeutics based?

Epion Therapeutics is headquartered in Burlington, United States, in the North America region.

How does Epion Therapeutics make money?

One revenue line is on record: epiSmart Cross-Linking System.

Who are Epion Therapeutics's main competitors?

iVeena Delivery Systems is listed as an emerging player. Broad incumbents are Carl Zeiss Meditec, Alcon, Nidek Co., Ltd., Johnson & Johnson Vision, Topcon Healthcare and Bausch + Lomb (Bausch Health). Direct peers are Glaukos Corporation and Avedro (now part of Glaukos). OCULUS Optikgeräte GmbH is listed as an others.

Does Epion Therapeutics have an API?

No public API is recorded for Epion Therapeutics.

What industry is Epion Therapeutics in?

Epion Therapeutics's product category is Ophthalmic medical devices. Its primary akta.pro industry code is HLAHAJAK, Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery), with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals